新冠病毒mRNA疫苗递送系统的中国专利风险  

Risk Analysis of Patent of COVID-19 mRNA Vaccine Delivery System in China

作　　者：润顺琪 熊壮壮 魏应亮 艾超仁 程珂 赵永江[1] RUN Shunqi;XIONG Zhuangzhuang;WEI Yingliang;AI Chaoren;CHENG Ke;ZHAO Yongjiang(Patent Examination Cooperation Hubei Center of the Patent Office,CNIPA,Wuhan 430000)

机构地区：[1]国家知识产权局专利局专利审查协作湖北中心,武汉430000

出　　处：《中国发明与专利》2022年第8期35-41,共7页China Invention & Patent

摘　　要：为抗击新冠病毒,各国政府和众多企业加速推进mRNA疫苗的研发。本文首先分析mRNA疫苗递送系统——脂质纳米颗粒(LNP)——的核心专利的稳定性,进一步结合国内企业的研发进展和专利披露信息,对涉及本土企业mRNA疫苗所使用的递送载体可能存在的侵权风险进行了分析,旨在为新冠病毒mRNA疫苗的研发和专利申请提供参考。In order to fight against the SARS-Cov-2,governments and many enterprises have accelerated the development of mRNA vaccines.Firstly,we analyzed the core patent stability of the lipid nanoparticle(LNP),which is one of the most commonly used delivery system of mRNA vaccine,furthermore,by investigating the research and information disclosed in patents of domestic companies,we evaluated the risks of infringement for domestic enterprises,aiming to provide a reference for the research and patent application of the COVID-19 mRNA vaccine.

关 键 词：新冠病毒 MRNA 疫苗 递送 脂质纳米颗粒 

分 类 号：G306[文化科学]